EZH2 and colorectal carcinoma: In the context of CRC, previously published work using commercially available CRC cell lines showed that EZH2 inhibition resulted in downregulation of the Wnt/β–catenin pathway and decreased CC-IC tumour-initiating capacity and mammosphere formation16.